Sign in
Taking peoplePhase 3

Tests tirzepatide against placebo in children with obesity

Tests tirzepatide with healthy lifestyle in children aged 6 to 11 with obesity.

Key facts

Who runs it
Eli Lilly and Company
Where
Seongnam-si and Seoul, South KoreaSee the 3 sitesAlso in 9 other countries, 79 sites
Registry title
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Status
Recruiting
Phase
Phase 3
People taking part
150 people, planned
Started
25 Sept 2026
Expected to end
Dec 2032
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tirzepatide
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 6 to less than 12 years who have obesity. Tirzepatide or placebo is added to a healthy lifestyle.

Age
6 to less than 12 years (Tanner stage 1 to 5)
Sex
Boys and girls can both join.
Disease stage
Obesity: BMI equal to or above the 95th percentile for age and sex. Body weight of at least 40 kg (88 pounds).
Earlier treatment
At least 1 unsuccessful effort to lose weight after a lifestyle program (diet and exercise counseling for at least 3 months).
Biomarker or test result
HbA1c must not be above 9.0% (75 mmol/mol) at screening.

Main reasons for not taking part

  • Weight reduction procedure done or planned, such as gastric bypass or sleeve gastrectomy
  • Obesity with a secondary cause (for example hypothalamic, monogenetic, syndromic or endocrine)
  • Type 1 diabetes, or a history of ketoacidosis or hyperosmolar state
  • History of proliferative diabetic retinopathy, diabetic macular edema, or nonproliferative diabetic retinopathy that needs acute treatment
  • Family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • J4M-MC-PW02
  • Are 6 to less than 12 years of age (Tanner stage 1 to 5 inclusive)
  • Have:; a body weight of ≥ 40 kilograms (kg) (88 pounds), and; been diagnosed with obesity, as defined by BMI equal to or above the 95th percentile for age and sex, on age- and sex-specific growth chart; J4M-MC-PWMP
  • Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening
  • Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022])

Who cannot take part

  • Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:; gastric bypass; sleeve gastrectomy; restrictive bariatric surgery, such as Lap-Band® gastric banding, or; any other procedure intended to result in weight reduction
  • Have a history of; proliferative diabetic retinopathy; diabetic macular edema, or; nonproliferative diabetic retinopathy that requires acute treatment; J4M-MC-PWMP
  • Have a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes
  • Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state
  • Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2
  • Have HbA1c >9.0% (75 mmol/mol) as measured by central laboratory at screening
  • J4M-MC-PW02

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 11 years old?

Where in South Korea

Also in 9 other countries, 79 sites

  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Jaehyun Kim (principal investigator)Not yet recruiting
  • Asan Medical CenterSeoul, South KoreaContact: Jin-Ho Choi (principal investigator)Not yet recruiting
  • Korea University Guro HospitalSeoul, South KoreaContact: Hyo-Kyoung Nam (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in the study will last about 104 weeks.

Read full original descriptionShow less

Participants who have completed the primary 104-week PW02 study (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.

The 2 groups in the trial

  • TirzepatideTreatment being tested

    Participants will receive tirzepatide subcutaneously (SC)

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Plain-language title
Tests tirzepatide against placebo in children with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07817875, who can take part
Record updated
4 November 2026